Cerenome 10-Q: Going Concern Warning, Nasdaq Equity Deficiency After $8.7M Q3 Loss
CNSY has more than doubled off its 52-week low of $0.429 on elevated volume (10× avg).
Summary
Cerenome booked its first $722 thousand of net diagnostic revenue but posted an $8.657 million Q3 net loss, ended with $879 thousand of cash and negative equity, and repeated its going-concern warning while expecting a Nasdaq minimum-equity deficiency notice.
Key Events · Earnings and Guidance · CNSY
-
First Diagnostic Revenue Booked
Net diagnostic revenue of $722 thousand in Q3 2026 was offset by $912 thousand of cost of revenue, leaving the Diagnostics segment with a $1.762 million operating loss.
-
Cash Falls to $879 Thousand
Cash and equivalents dropped to $879 thousand from $4.256 million at December 31, 2025, with $3.992 million of investments; nine-month operating cash burn was $21.044 million and working capital is a $5.056 million deficit.
-
Going Concern and Nasdaq Deficiency
Management cites substantial doubt about continuing as a going concern with negative stockholders' equity of $923 thousand, and expects a Nasdaq Rule 5550(b) notice after equity fell below $2.5 million and listed-securities value stayed under $35 million for 30 business days.
-
Only $3.0M of $20M Facility Drawn
The 3i, LP senior secured convertible note closed at $3.0 million of a $20.0 million commitment; the $2.0 million second tranche needs an effective resale registration statement and the remaining $15.0 million is subject to further closing conditions.
Analysis · CNSY · Life Sciences
The quarter's headline is the first real product revenue — $722 thousand of net CNSide diagnostic revenue — but it came with $912 thousand of cost of revenue, so the diagnostics segment still lost money on a gross basis. Against that, the company burned $21.0 million of operating cash in nine months and ended September with $879 thousand of cash plus $3.992 million of investments, a $5.056 million working-capital deficit and negative stockholders' equity of $923 thousand. Management states plainly that these factors raise substantial doubt about the ability to continue as a going concern, and it expects a Nasdaq notice that it fails the $2.5 million minimum stockholders' equity standard (the stock has also closed below $1.00 since November 4, 2026). The 3i, LP senior secured convertible note is the lifeline: only $3.0 million of the $20.0 million commitment has been drawn, the remaining tranches require an effective resale registration statement and stockholder approval, and the note is secured by substantially all assets including CNSide's intellectual property. Post-quarter ATM sales of 1,934,812 shares for about $3.8 million keep the lights on but also force partial note redemptions at 105%.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNSY was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.43 to $18.89. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.